Rong Deng - Concepedia

Author

Rong Deng

Sichuan University ORCID

Also Known As

Bei Wang, Bogusaw Okopie, Deng Rong, R Deng, R. Deng, Ranxi Deng, Rong DENG, Rong Deng, Rong-hai Deng, Rongzheng Deng

121

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Sichuan University West China Hospital of Sichuan University Gene Therapy Laboratory Kaiser Permanente South San Francisco Medical Center University of California, San Francisco

About

Rong Deng is an author at Sichuan University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	20	1.4K
2	Allergy	2	2	325
3	Biostatistics	2	2	296
4	Health Sciences	1	1	16
5	Nursing	1	1	204

Rong Deng

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data Rong Deng, Suhasini Iyer, Frank‐Peter Theil, mAbs Therapeutic Drug MonitoringTranslational MedicineAllergyPreclinical Drug EvaluationHuman Pharmacokinetics	2011	270
A strategy for risk mitigation of antibodies with fast clearance Isidro Hötzel, Frank‐Peter Theil, L. Bernstein, mAbs	2012	246
Prevalence and associated factors of depression and anxiety among nurses during the outbreak of COVID-19 in China: A cross-sectional study Rujun Zheng, Yuhong Zhou, Yan Fu, International Journal of Nursing Studies NursingPsychological Co-morbiditiesPsychiatryMental Health NursingCovid-19 Pandemic	2020	204
Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor Rong Deng, Daniela Bumbaca, Cinthia V. Pastuskovas, mAbs Radioactivity RatioImmunologyImmunotherapeuticsImmunotherapyOncology	2016	196
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge Bing Li, Devin B. Tesar, C. Andrew Boswell, mAbs Framework SelectionDrug TargetImmunocytochemical TechniqueImmunologyImmunodominance	2014	119
Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys Rong Deng, Kelly M. Loyet, Samantha Lien, Drug Metabolism and Disposition	2010	108
A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- <i>Staphylococcus aureus</i> Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers Melicent C. Peck, Michael E. Rothenberg, Rong Deng, Antimicrobial Agents and Chemotherapy	2019	98
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients Julie H. Ishida, Anita Patel, Aneesh K. Mehta, Antimicrobial Agents and Chemotherapy	2016	94
Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma Andrew G. Polson, Marna Williams, Aimee Gray, Leukemia Lymphoid NeoplasiaMedicineAntibody-drug ConjugateImmunologyImmune Checkpoint Inhibitor	2010	88
DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma Dongwei Li, Kirsten Achilles Poon, Shang‐Fan Yu, Molecular Cancer Therapeutics ImmunologyImmunotherapeuticsImmunotherapyTumor BiologyOncology	2013	83

Page 1